Inrebic (fedratinib) / BMS  >>  Phase 1
Welcome,         Profile    Billing    Logout  

3 Trials

   Remove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Inrebic (fedratinib) / BMS
NCT03983161: A Pharmacokinetics and Tolerability Study of Fedratinib in Subjects With Moderate and Severe Hepatic Impairment

Completed
1
39
US
Fedratinib
Celgene, Impact Biomedicines, Inc., a wholly owned subsidiary of Celgene Corporation
Healthy Volunteers, Hepatic Impairment
01/23
01/23
NCT04955938: A Study of Fedratinib With IDH Inhibition in Advanced-Phase, IDH-Mutated Ph-Negative Myeloproliferative Neoplasms

Recruiting
1
50
US
Ivosidenib, Tibsovo, Enasidenib, IDHIFA, Fedratinib, INREBIC
University of Chicago
IDH Mutation, IDH1 Mutation, IDH2 Gene Mutation, Blood Cancer, Myeloproliferative Neoplasm
10/25
10/25
NCT05524857: Combination of Fedratinib and Decitabine for Myeloproliferative Neoplasms (MPN)- Accelerated Phase (AP)/Blast Phase (BP)

Terminated
1
2
US
Fedratinib Oral Capsule 300 mg, Inrebic, Decitabine 20 mg/m2, Dacogen, Fedratinib Oral Capsule 400 mg
Joseph Jurcic, Bristol-Myers Squibb
Myeloproliferative Neoplasm
04/24
04/24

Download Options